KERYX BIOPHARMACEUTICALS INC
KERYX BIOPHARMACEUTICALS INC (KERYX): 2 pipeline candidates · ~9 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.6 months
D/E -3.80 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for KERYX BIOPHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$41.1M
Quarterly Burn
$23.4M
Runway
8.6 mo
Revenue
$28.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in KERYX BIOPHARMACEUTICALS INC's pipeline?
KERYX BIOPHARMACEUTICALS INC (KERYX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KERYX BIOPHARMACEUTICALS INC's lead drug candidate?
KERYX BIOPHARMACEUTICALS INC's most advanced tracked candidate is auryxia (Approved) for Treatment of iron deficiency anemia in adults with CKD, not on dialysis.
What is KERYX BIOPHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KERYX BIOPHARMACEUTICALS INC has approximately 8.6 months of cash runway.
Who is the CEO of KERYX BIOPHARMACEUTICALS INC?
Jodie P. Morrison Interim is the chief executive officer of KERYX BIOPHARMACEUTICALS INC (KERYX).
Get the full picture on KERYX BIOPHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.